Published March, 2014
By Mark S. Micozzi
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

---

Published June, 2013
By Michael A. Kaliner
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

---

Published May, 2012
By Kenneth D. Tew and Gary D. Kruh
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

---

Published February, 2012
By Julien Bogousslavsky and Marc Fisher
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

---

Published November, 2011
By Dieter Naber and Martin Lambert
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

---

Published September, 2011
By Frank Ling, Thomas G. Stovall, B. Zite Nikki, Alice W. Chuang, Todd T. Tillmanns and Thomas Stovall
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

With contributions by numerous experts

---

Published November, 2009
By David Staskin
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

Here is the largest and highest-quality collection of images relating to all areas of bladder disease and dysfunction, from epidemiology, pathophysiology, and genetics, to imaging, therapy, rehabilitation, and comorbidities.

---

Published October, 2009
By Norman K. Hollenberg
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

In this new, four-color edition, one-third of the chapters is new, and half of them are written by new authors. Expanded topics include home blood pressure, secondary hypertension, and information on newer agents such as nebivolol and aliskiren.

---

Published April, 2009
By Peter Libby
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

This four-color atlas takes a comprehensive look at all pertinent areas of cardiovascular disease. It includes detailed legends and extensive reference listings for hundreds of illustrations, algorithms, schematics, and images.

---

Published April, 2009
By J G Reves, Scott Reeves, Jake Abernathy and James H Abernathy, III
Publisher: Springer (Current Medicine Group)
Rating: 1.00
in-stock

---